Open Access
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
Article Number 03060
Number of page(s) 7
Section Environmental Sustainable Development and Industrial Transformation
Published online 09 September 2021
  1. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine | Business Wire. 2021. [Google Scholar]
  2. Coronavirus disease (COVID-19): situation report, 164. 2021. [Google Scholar]
  3. Gopinathan, U., et al., R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition. 2020: Infectious Diseases in the New Millennium. [Google Scholar]
  4. van Riel, D. and E. de Wit, Next-generation vaccine platforms for COVID-19. Nat Mater, 2020. 19(8): p. 810-812. [PubMed] [Google Scholar]
  5. McCloskey, B., et al., Mass gathering events and reducing further global spread of COVID-19: a political and public health dilemma. Lancet, 2020. 395(10230): p. 1096-1099. [PubMed] [Google Scholar]
  6. Vaccines and immunization. 2021. [Google Scholar]
  7. Hu, B., et al., Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol, 2021. 19(3): p. 141-154. [CrossRef] [PubMed] [Google Scholar]
  8. SARS-CoV-2 Variants of Concern | CDC. 2021. [Google Scholar]
  9. Inactivated vaccine - Wikipedia. 2021. [Google Scholar]
  10. Vaccine Types | 2021. [Google Scholar]
  11. What is an Inactivated Vaccine?. 2021. [Google Scholar]
  12. Sharma, O., et al., A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol, 2020. 11: p. 585354. [PubMed] [Google Scholar]
  13. Adjuvants and Vaccines | Vaccine Safety | CDC. 2021. [Google Scholar]
  14. Sinopharm, Sinovac COVID-19 vaccine data show efficacy: WHO | Reuters. 2021. [Google Scholar]
  15. Sinopharm’s COVID-19 Vaccine Shows 86% Efficacy, UAE Health Agency Says | BioSpace. 2021. [Google Scholar]
  16. Full list of adverse reactions from China’s Sinopharm vaccine revealed | Taiwan News | 2021/01/11. 2021. [Google Scholar]
  17. Vaccine Basics | 2021. [Google Scholar]
  18. Kyuri, L., et al., Development of mRNA vaccines and their prophylactic and therapeutic applications. Nano Research, 2018. 11: p. 5173-5192. [Google Scholar]
  19. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. [Google Scholar]
  20. Meo, S.A., et al., COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. 2021. [Google Scholar]
  21. Jackson, L.A., et al., An mRNA vaccine against SARS-COV-2 — Preliminary report. New England Journal of Medicine, 2020. 383(20). [Google Scholar]
  22. Yadav, T., et al., Recombinant vaccines for COVID-19. Human Vaccines & Immunotherapeutics, 2020. 16(12): p. 2905-2912. [PubMed] [Google Scholar]
  23. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Novavax Inc. -IR Site. 2021. [Google Scholar]
  24. Ewer, K.J., et al., Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol, 2016. 41: p. 47-54. [CrossRef] [PubMed] [Google Scholar]
  25. Schiedner, G., et al., Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet, 1998. 18(2): p. 180-3. [PubMed] [Google Scholar]
  26. Ewer, K.J., et al., Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol, 2016. 41: p. 47-54. [CrossRef] [PubMed] [Google Scholar]
  27. Izda, V., M.A. Jeffries and A.H. Sawalha, COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol, 2021. 222: p. 108634. [PubMed] [Google Scholar]
  28. Wei, C. and Hao, Q., Academician Wei Chen’s COVID-19 vaccine clinical trial results released: all 108 volunteers developed an immune response. Science Grand View Garden, 2020(11): page 4. [Google Scholar]
  29. Zhu, F.C., et al., Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 2020. 395(10240): p. 1845-1854. [PubMed] [Google Scholar]
  30. Soleimanpour, S. and A. Yaghoubi, COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines, 2021. 20(1): p. 23-44. [Google Scholar]
  31. Ura, T., et al., New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine, 2021. 39(2): p. 197-201. [PubMed] [Google Scholar]
  32. Colloca, S., et al., Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med, 2012. 4(115): p. 115ra2. [PubMed] [Google Scholar]
  33. Shahcheraghi, S.H., et al., An overview of vaccine development for COVID-19. Ther Deliv, 2021. 12(3): p. 235-244. [Google Scholar]
  34. Ura, T., K. Okuda and M. Shimada, Developments in Viral Vector-Based Vaccines. Vaccines (Basel), 2014. 2(3): p. 624-41. [PubMed] [Google Scholar]
  35. Yu, X., Xin, X. and Jin, Y., Research progress of type 5 adenovirus vector and thrombocytopenia. Journal of Modern Laboratory Medicine, 2011. 26(5): pp. 160-161. [Google Scholar]
  36. Wibawa, T., Covid-19 vaccine research and development: ethical issues. Trop Med Int Health, 2021. 26(1): p. 14-19. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.